Myriad Partners with BioMarin on PARP Inhibitor

Myriad's BRACAnalyis will be used as a companion diagnostic as BioMarin develops its PARP inhibitor drug candidate for patients with advanced or recurrent tumors.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.